

[全部](#)[图片](#)[新闻](#)[视频](#)[更多](#)[设置](#)[工具](#)

找到约 395,000 条结果 (用时 0.72 秒)

Following the results of the EMPA-REG OUTCOME trial with ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5245975/> - 翻译此页

作者：FJ Ampudia-Blasco - 2017 - 被引用次数：6 - 相关文章

2017年1月13日 - The recently published **cardiovascular outcomes data** for the first sodium–glucose ... empagliflozin in the EMPA-REG OUTCOME study could be seen as a “**class effect**”, ... Moreover, compared with SGLT6, **both** empagliflozin and ... without previous **hypoglycemic treatment**) or <10% (patients with previous ...

Comparative safety for cardiovascular outcomes of DPP-4 inhibitors ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484219/> - 翻译此页

作者：HJ Chin - 2017 - 被引用次数：6 - 相关文章

2017年6月23日 - In the EXAMINE (examination of cardiovascular outcomes **with** alogliptin ... **using real-world data** to evaluate cardiovascular outcome risks; or DPP-4 inhibitors compared with the use of oral **antidiabetic drugs** in patients with diabetes. Heart failure and mortality outcomes in patients with type 2 diabetes ...

A Real-World Evaluation of the Association between Cardiovascular ...

diabetes.diabetesjournals.org/content/67/Supplement_1/1493-P - 翻译此页

作者：E THIEL - 2018

Data from placebo controlled, randomized clinical trials (RCTs) have demonstrated cardio-protective **effects** of certain diabetes **therapy classes**, including ...

Name of Journal: *World Journal of Diabetes*

Manuscript No: 41697

Manuscript Type: ORIGINAL ARTICLE

Observational Study

Using real world data to assess cardiovascular outcomes of two antidiabetic treatment classes

Stapff MP. Real world data and cardiovascular outcomes

Manfred Paul Stapff

Abstract

Match Overview

1	Internet 46 words crawled on 23-Nov-2017 diva-portal.org	2%
2	Crossref 27 words Shan Li, Jian Li, Xin-Lan Guan, Jun Li, Sheng-Ping Deng, Lu-Qing Li, Mao-Tong Tang, Ji-Guo Huang, Zi-Zhan Chen, R	1%
3	Internet 23 words crawled on 19-Aug-2018 sushiandpassion.blogspot.com	1%
4	Internet 18 words crawled on 02-Jun-2018 pubs.acs.org	1%
5	Internet 14 words crawled on 30-Oct-2017 circ.ahajournals.org	1%

找到约 809,000 条结果 (用时 0.68 秒)

[A Real-World Evaluation of the Association between Cardiovascular ...](#)

diabetes.diabetesjournals.org/content/67/Supplement_1/1493-P - [翻译此页](#)

作者: E THIEL - 2018

Abstract. **Data** from placebo controlled, randomized clinical trials (RCTs) have demonstrated ... The relative risks of events in the 12 months before and after **treatment** initiation were ... DPP-4 Inhibitors—Analysis from the CVD-REAL 2 Study ... **Cardiovascular outcomes** associated **with** canagliflozin versus other non-gliflozin ...

[The Cardiovascular Benefits Associated with the Use of Sodium ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954590/> - [翻译此页](#)

作者: G Baptist - 2018 - 被引用次数: 1 - [相关文章](#)

跳到 **Cardiovascular outcome** trials on sodium-glucose cotransporter 2 ... - As a **class**, the SGLT2 inhibitors ... that **treatment with** SGLT2 inhibitors ... The Canagliflozin **Cardiovascular Assessment** Study ... While these **data** suggest that a **class** effect of ... **Antidiabetic therapy** has to be ... CVD-REAL, **Real-world** ...

[Cardiovascular outcomes and safety with antidiabetic drugs - NCBI - NIH](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124835/> - [翻译此页](#)

作者: KK Aldossari - 2018

Some **classes** of **drugs** demonstrate CV protection, some of them may be a result of a ... [1] The World Health Organization stated that Saudi Arabia ranks 7th globally in terms **Cardiovascular outcome** trials for **antidiabetics** (TZDs) in type 2 diabetes ... The 'Diabetes Reduction **Assessment with** Ramipril and Rosiglitazone ...

[New real-world data analysis finds no evidence of increased risk of ...](#)

<https://www.astrazeneca.com/.../real-world-data-saxagliptin-sitagliptin-heart-...> [翻译此页](#)

2015年6月8日 - "These new **data** provide valuable **real-world** information regarding the ... for DPP-4 inhibitors, and specifically for saxagliptin relative to sitagliptin, within this **class**. ... **Assessment of Vascular Outcomes** Recorded in Patients **with** ... **Cardiovascular Risk** in New **Antidiabetic Therapies to Treat** Type 2 Diabetes.